Ryan Watts, CEO of Denali Therapeutics, explains why it’s an incredible time for neuroscience, the focus of Denali’s clinical portfolio, and the role of biomarkers in our ability to follow neurodegenerative disease. More from Flagship @ JPM2023 here.
If you see an error in this story, contact us.
Related Companies
- Denali Therapeutics Founded: 2015
